Cellectar Biosciences, Inc.
CLRB
$2.36
-$0.15-5.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.29% | -61.26% | -70.29% | -42.63% | -39.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.48% | -55.35% | -63.60% | -55.94% | -46.67% |
| Operating Income | 9.48% | 55.35% | 63.60% | 55.94% | 46.67% |
| Income Before Tax | 14.39% | -131.29% | 69.70% | -492.55% | 75.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.39% | -124.81% | 69.70% | -492.55% | 75.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.39% | -124.81% | 69.70% | -492.55% | 75.21% |
| EBIT | 9.48% | 55.35% | 63.60% | 55.94% | 46.67% |
| EBITDA | 9.52% | 55.50% | 63.81% | 56.14% | 46.74% |
| EPS Basic | 68.99% | 23.51% | 87.43% | -339.78% | 84.21% |
| Normalized Basic EPS | 68.99% | 21.30% | 87.43% | -339.75% | 84.21% |
| EPS Diluted | 68.99% | 23.51% | 88.38% | 37.54% | 84.21% |
| Normalized Diluted EPS | 68.99% | 21.30% | 87.29% | -359.81% | 84.21% |
| Average Basic Shares Outstanding | 176.05% | 193.89% | 141.15% | 34.74% | 57.02% |
| Average Diluted Shares Outstanding | 176.05% | 193.89% | 138.37% | 28.89% | 57.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |